GlassScriptPhysician profile
Phillip A Paspa
NPI 1184625188
$9,527.89
in general payments reported to CMS, 2019-2025
41 companies · $3,665 in 2025
The $3,665 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $549 · 2021: $1,127 · 2022: $968 · 2023: $949 · 2024: $1,020 · 2025: $3,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,558 · Travel and Lodging: $2,067 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,557.64 |
| Travel and Lodging | $2,067.28 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,743.43 | 2021-2025 | Aveir, Assurity, Amplatzer |
| Abiomed | $950.19 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $809.51 | 2019-2022 | |
| Amgen INC. | $804.49 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $746.14 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $490.20 | 2019-2025 | |
| Medtronic, INC. | $414.03 | 2021-2025 | Symplicity G3, Onyx Frontier, Arctic Front Advance |
| Novartis Pharmaceuticals Corporation | $382.94 | 2019-2025 | |
| Boston Scientific Corporation | $263.10 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.36 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.52 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $165.34 | 2019-2022 | |
| Shockwave Medical, INC | $142.77 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $141.70 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $140.01 | 2019-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Paspa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.